Myeloproliferative neoplasm Medical Services in China

Myeloproliferative neoplasms (MPNs) are a group of clonal hematopoietic stem cell disorders characterized by the overproduction of mature blood cells—primarily red blood cells, white blood cells, and/or platelets—in the bone marrow. The classic Philadelphia chromosome–negative MPNs include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). These conditions arise from acquired somatic mutations—most commonly in the JAK2 gene (present in >95% of PV and ~60% of ET/PMF cases), but also in CALR and MPL—leading to constitutive activation of the JAK-STAT signaling pathway and uncontrolled myeloid proliferation. While the exact triggers remain unclear, aging is the strongest epidemiologic correlate: MPNs predominantly affect adults over age 60, with median diagnosis ages ranging from 60 to 65 years. Incidence estimates vary globally but average approximately 1–2 cases per 100,000 person-years for PV and ET, and 0.5–1.5 per 100,000 for PMF. Prevalence is higher due to chronic disease course—estimated at 22–57 per 100,000 for PV and ET, and up to 10 per 100,000 for PMF. Risk factors include advancing age, male sex (slightly higher incidence in PV and PMF), and possibly environmental exposures such as ionizing radiation or benzene; however, no strong hereditary pattern or modifiable lifestyle risk has been consistently established. Importantly, MPNs are not contagious nor caused by infection. Quality of life is significantly impacted—not only by physical symptoms (e.g., fatigue, pruritus, night sweats, early satiety, bone pain, splenomegaly-related discomfort) but also by psychological burden, including anxiety about thrombotic events, disease progression to acute myeloid leukemia (10–20% lifetime risk in PMF), and treatment-related side effects. Patients often report impaired work productivity, sleep disruption, and social withdrawal. Symptom burden correlates poorly with blood counts, underscoring the importance of patient-reported outcomes in clinical assessment. Long-term management focuses on risk stratification (age, prior thrombosis, mutation profile, blood counts), cytoreduction (hydroxyurea, interferon-alpha, ruxolitinib), anticoagulation, and supportive care—including phlebotomy in PV and transfusion support in advanced myelofibrosis. With modern therapies, many patients live for decades, especially those with ET or low-risk PV; however, PMF carries a more variable prognosis, with median survival ranging from 1.5 to 15+ years depending on molecular and clinical risk factors.

Myeloproliferative neoplasms (MPNs) are a group of clonal hematopoietic stem cell disorders characterized by excessive production of mature blood cells—primarily granulocytes, erythrocytes, and/or platelets—without significant dysplasia or immaturity. The primary cause of classical BCR-ABL1–negative MPNs—including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF)—is the acquisition of somatic driver mutations in genes regulating the JAK-STAT signaling pathway. The most prevalent is the JAK2 V617F mutation, present in approximately 95% of PV cases and 50–60% of ET and PMF cases. This gain-of-function mutation leads to constitutive activation of JAK2 kinase, resulting in cytokine-independent proliferation of myeloid progenitors. Additional driver mutations include exon 12 mutations in JAK2 (in JAK2 V617F–negative PV), CALR mutations (found in ~25–30% of ET and ~50–60% of PMF cases, predominantly type 1 and type 2 frameshift variants), and MPL mutations (W515K/L/A, occurring in ~3–5% of ET and ~5–10% of PMF). These mutations converge on hyperactivation of the thrombopoietin receptor (MPL)–JAK2–STAT axis, promoting unchecked megakaryocytic and erythroid expansion.

While these somatic mutations are necessary for clonal dominance and disease initiation, they are insufficient alone to explain full phenotypic expression, progression, or heterogeneity. Secondary genetic events—including ASXL1, TET2, DNMT3A, EZH2, SRSF2, IDH1/2, and U2AF1 mutations—accumulate over time and contribute to disease acceleration, bone marrow fibrosis, leukemic transformation (to secondary acute myeloid leukemia), and adverse prognosis. These so-called 'high-molecular-risk' mutations impair epigenetic regulation, RNA splicing, and DNA methylation, fostering genomic instability and clonal evolution.

No definitive environmental triggers have been established for MPN onset; however, epidemiologic studies suggest potential associations requiring further validation. Prior exposure to ionizing radiation—such as therapeutic radiation or atomic bomb survivor cohorts—has shown modestly increased risk, though data remain inconsistent. Occupational exposure to benzene and certain organic solvents has been implicated in some case-control studies, but causality is unproven and confounded by coexposures. There is no robust evidence linking MPNs to common environmental toxins, pesticides, or dietary factors. Notably, MPNs are not associated with viral infections, autoimmune conditions, or chronic inflammation as direct etiologies—though inflammation may modulate disease phenotype and symptom burden once established.

Genetic predisposition plays a role beyond acquired somatic mutations. Germline polymorphisms in the JAK2 locus (e.g., the 46/1 haplotype) significantly increase susceptibility to acquiring the JAK2 V617F mutation, likely by facilitating recombination or mutagenesis during hematopoiesis. Genome-wide association studies have identified additional susceptibility loci near TERT, SH2B3, and HBS1L-MYB, implicating telomere maintenance, cytokine signaling modulation, and hematopoietic transcriptional regulation in inherited risk. Familial clustering occurs in ~7–10% of MPN patients, suggesting polygenic inheritance patterns rather than Mendelian transmission. First-degree relatives of MPN patients carry a 5- to 7-fold increased risk, independent of shared environment.

Established demographic and clinical risk factors include advancing age (median diagnosis age: 60–65 years), male sex (particularly for PV and PMF), and prior history of other hematologic malignancies (e.g., preceding clonal cytopenias or CHIP). Cardiovascular risk factors—including hypertension, diabetes, smoking, and hyperlipidemia—do not cause MPNs but substantially amplify thrombotic risk, the leading cause of morbidity and mortality in ET and PV. Splenomegaly, leukocytosis (>11 × 10⁹/L), and advanced age (>60 years) are validated clinical risk factors for thrombosis in ET and PV. In PMF, dynamic prognostic models (e.g., DIPSS-plus) incorporate hemoglobin <10 g/dL, leukocyte count >25 × 10⁹/L, circulating blasts ≥1%, constitutional symptoms, transfusion dependence, and unfavorable karyotype to stratify survival and leukemic transformation risk. Importantly, MPNs are not linked to immunosuppression, HIV, or iatrogenic causes such as chemotherapy-induced mutagenesis—unlike therapy-related myeloid neoplasms. Overall, MPNs arise from stochastic somatic mutagenesis in genetically predisposed individuals, with disease behavior shaped by the interplay of driver and subclonal mutations, host inflammatory milieu, and comorbid vascular risk burden.

Myeloproliferative neoplasms (MPNs) are a group of clonal hematopoietic stem cell disorders characterized by excessive production of mature blood cells—most commonly granulocytes, erythrocytes, or platelets—without significant dysplasia or immaturity. The principal classical BCR–ABL1-negative MPNs include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). Early symptoms are often nonspecific and insidious, reflecting chronic cytokine-mediated inflammation and subtle organ infiltration rather than overt cytopenias or blast proliferation. Patients may report persistent fatigue (reported in up to 70% of cases), low-grade fevers, night sweats, unintentional weight loss (>10% body weight over six months), and generalized pruritus—particularly aquagenic pruritus, which occurs within minutes of water exposure and is highly suggestive of PV due to aberrant mast cell activation and histamine release. Early constitutional symptoms may be attributed erroneously to stress, aging, or depression, delaying diagnosis by months to years. Headache, dizziness, visual disturbances (e.g., scintillating scotomata), and paresthesias may reflect hyperviscosity or microvascular disturbances, especially in PV with elevated hematocrit (>49% in men, >48% in women) or in ET with extreme thrombocytosis (>1,000 × 10⁹/L). Early splenomegaly is frequently asymptomatic but may manifest as early satiety, left upper quadrant discomfort, or postprandial bloating.

Typical symptoms evolve with disease progression and vary by MPN subtype. In PV, hallmark features include plethora (ruddy cyanosis), hypertension (often newly diagnosed or refractory), and thrombotic events—both arterial (e.g., transient ischemic attack, myocardial infarction, digital ischemia) and venous (e.g., splanchnic vein thrombosis—including Budd–Chiari syndrome, portal vein thrombosis, mesenteric vein thrombosis—which occur at rates 10–50× higher than in the general population). ET typically presents with microvascular symptoms such as erythromelalgia (burning pain, redness, and warmth in hands/feet, often relieved by cooling), digital ischemia, or migraine-like headaches; macrovascular thrombosis (stroke, deep vein thrombosis) is also common. PMF is distinguished by progressive splenomegaly (often massive, palpable >10 cm below costal margin), debilitating fatigue, bone pain (due to marrow fibrosis and osteosclerosis), and early satiety from splenic compression. Cachexia, fever, and profound anemia (hemoglobin <10 g/dL) are more frequent in PMF than in PV or ET.

Accompanying symptoms reflect systemic inflammation and extramedullary hematopoiesis. Elevated proinflammatory cytokines—including IL-6, TNF-α, and TGF-β—drive constitutional symptoms and contribute to bone remodeling abnormalities (e.g., osteosclerosis on imaging). Gout and uric acid nephropathy arise from increased cell turnover and purine catabolism, particularly after phlebotomy or cytoreduction. Microangiopathic hemolytic anemia may occur in advanced PMF or post-PV/ET myelofibrosis. Patients may develop acquired von Willebrand syndrome (type 2A) in ET with extreme thrombocytosis, leading to mucocutaneous bleeding despite high platelet counts. Hepatomegaly, lymphadenopathy, and pulmonary hypertension (secondary to chronic hypoxia or portopulmonary shunting in splanchnic thrombosis) are less common but clinically significant.

Complications define long-term morbidity and mortality. Thrombosis remains the leading cause of death in PV and ET, while in PMF, progression to acute myeloid leukemia (AML) carries the worst prognosis—occurring in ~10–20% of patients over 10 years, often associated with high-risk mutations (e.g., ASXL1, SRSF2, IDH1/2, U2AF1). Myelofibrotic transformation (post-PV or post-ET MF) develops in ~10–15% of PV and ~5% of ET patients over a decade, heralded by worsening anemia, rising lactate dehydrogenase (LDH), circulating blasts (>1%), and teardrop poikilocytes on peripheral smear. Portal hypertension, esophageal varices, and ascites may complicate splanchnic vein thrombosis. Extramedullary hematopoiesis in the lungs (pulmonary parenchymal or pleural), spine (causing cord compression), or skin (leukemia cutis) portends aggressive disease. Iron deficiency anemia from chronic gastrointestinal bleeding (e.g., angiodysplasia in Heyde syndrome, associated with acquired von Willebrand disease) further exacerbates fatigue and cardiac strain.

Diagnosis relies on integrated clinical, morphologic, molecular, and laboratory assessment per WHO 2022 criteria. Essential components include complete blood count with peripheral blood smear (evaluating for leukoerythroblastosis, teardrop cells, nucleated RBCs, megakaryocyte morphology), bone marrow biopsy with reticulin and collagen staining (to grade fibrosis: MF-0 to MF-3), cytogenetics (karyotype), and molecular testing for driver mutations: JAK2 V617F (present in >95% of PV, ~60% of ET/PMF), JAK2 exon 12 (PV only), CALR (type 1/type 2 deletions/insertions in ~25–30% of ET/PMF), and MPL (W515K/L in ~3–5% of ET/PMF). Absence of BCR–ABL1 fusion (by RT-PCR or FISH) is mandatory. Serum erythropoietin (EPO) level is low or suppressed in PV but normal or elevated in secondary erythrocytosis and most ET/PMF. Additional supportive tests include LDH (elevated in PMF and disease activity), serum ferritin, vitamin B12, and uric acid.

Differential diagnosis must rigorously exclude reactive and secondary causes. Secondary erythrocytosis (e.g., chronic hypoxia, sleep apnea, high-altitude residence, renal tumors, EPO-secreting neoplasms) is distinguished by elevated serum EPO and absence of clonal markers. Reactive thrombocytosis (e.g., infection, iron deficiency, malignancy, surgery, inflammation) shows normal platelet morphology, absence of JAK2/CALR/MPL mutations, and resolution with underlying condition treatment. Chronic myeloid leukemia (CML) mimics MPNs but is defined by BCR–ABL1 positivity and presence of basophilia, eosinophilia, and splenomegaly; distinction is critical given tyrosine kinase inhibitor therapy. Other differentials include myelodysplastic/myeloproliferative neoplasms (e.g., chronic myelomonocytic leukemia—characterized by monocytosis >1 × 10⁹/L and dysplasia), acute leukemias (with ≥20% blasts), and non-clonal bone marrow failure syndromes. Rare mimics include hereditary erythrocytosis (e.g., VHL, EPAS1/HIF2A mutations) and familial thrombocytosis (e.g., THPO or MPL germline variants). Accurate classification guides risk-adapted therapy—ranging from aspirin and phlebotomy in low-risk PV to ruxolitinib or fedratinib in symptomatic MF—and informs prognostication using validated tools (e.g., IPSS, MIPSS70+, GIPSS).

Myeloproliferative neoplasms (MPNs) are a group of clonal hematopoietic stem cell disorders characterized by excessive production of mature blood cells—most commonly erythrocytes, granulocytes, or platelets. The three classic BCR-ABL1–negative MPNs include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). Treatment is risk-adapted, aiming to reduce thrombotic and hemorrhagic complications, alleviate constitutional symptoms, prevent disease progression (e.g., to accelerated phase or blast-phase acute myeloid leukemia), and improve quality of life and overall survival.

Conservative management forms the cornerstone of early-stage or low-risk MPN care. For low-risk PV (age <60 years, no prior thrombosis) and low-risk ET (age <60 years, no prior thrombosis or JAK2 mutation-associated high platelet count), observation with regular clinical and laboratory monitoring (CBC every 3–6 months, serum ferritin, LDH, uric acid) may be appropriate. Lifestyle modifications—including smoking cessation, weight optimization, hypertension and diabetes control, and avoidance of estrogen-containing contraceptives—are strongly recommended to mitigate cardiovascular risk. Phlebotomy remains first-line conservative therapy in PV: target hematocrit <45% is maintained via scheduled venesection (typically 250–500 mL weekly or biweekly until goal achieved), followed by maintenance phlebotomy as needed. Iron deficiency induced by repeated phlebotomy must be monitored but generally not supplemented unless symptomatic anemia develops, as iron repletion may exacerbate erythropoiesis and thrombotic risk. Low-dose aspirin (75–100 mg daily) is indicated for nearly all PV patients without contraindications (e.g., major bleeding history or active peptic ulcer disease) and for most ET patients—particularly those with microvascular symptoms (e.g., erythromelalgia, transient ischemic attacks) or JAK2 V617F positivity—to reduce thrombotic events by up to 60%.

Pharmacologic therapy is initiated based on risk stratification. High-risk PV (age ≥60 years or prior thrombosis) and high-risk ET (same criteria plus cardiovascular risk factors) require cytoreduction. First-line agents include hydroxyurea—a ribonucleotide reductase inhibitor that effectively controls blood counts and reduces thrombosis risk—with long-term safety supported by decades of clinical use. Alternative cytoreductive agents include interferon-alpha (IFN-α), particularly pegylated formulations (e.g., peginterferon alfa-2a), which demonstrate molecular response rates (reduction in JAK2 V617F allele burden) and favorable tolerability in younger patients and those desiring pregnancy preservation. Ruxolitinib, a JAK1/JAK2 inhibitor, is FDA- and EMA-approved for intermediate- or high-risk PMF and for PV patients resistant/intolerant to hydroxyurea. It significantly improves splenomegaly, constitutional symptoms (e.g., night sweats, weight loss, pruritus), and quality-of-life metrics, though it does not eliminate the malignant clone or consistently reduce allele burden. Additional agents under investigation or used off-label include busulfan (especially in elderly patients), pipobroman, and novel agents such as fedratinib and pacritinib for specific MF subpopulations (e.g., thrombocytopenic MF). Antifibrotic and disease-modifying strategies remain investigational; allogeneic hematopoietic stem cell transplantation (allo-HSCT) is currently the only potentially curative modality—but reserved exclusively for fit patients with high-risk PMF or post-MPN AML due to substantial treatment-related mortality (15–30%).

Surgical intervention has no primary role in MPN management. Splenectomy may be considered in select PMF or post-PV/ET MF patients with massive, symptomatic splenomegaly refractory to medical therapy (e.g., ruxolitinib), severe cytopenias due to hypersplenism, or mechanical complications (e.g., gastric compression, left upper quadrant pain). However, splenectomy carries significant risks—including overwhelming postsplenectomy infection (OPSI), pulmonary hypertension, rapid disease acceleration, and increased thrombotic risk—and should only be performed after multidisciplinary evaluation at experienced centers. Laparoscopic approaches are preferred when feasible, and lifelong penicillin prophylaxis and pneumococcal/meningococcal/H. influenzae vaccination are mandatory preoperatively.

China offers distinct advantages in MPN care, anchored in its rapidly evolving hematology infrastructure. Over 30 national MPN referral centers—including Peking University People’s Hospital, Shanghai Ruijin Hospital, and the First Affiliated Hospital of Sun Yat-sen University—participate in prospective registries (e.g., China MPN Registry) and multicenter clinical trials evaluating novel JAK inhibitors, interferon regimens, and combination therapies. Chinese regulatory approval pathways (NMPA) have accelerated access to ruxolitinib and recently approved fedratinib, with biosimilar development enhancing affordability. Integrated traditional Chinese medicine (TCM) is frequently incorporated adjunctively—not as monotherapy, but as evidence-informed supportive care: standardized herbal formulas (e.g., Bushen Huoxue decoction) have demonstrated adjunctive benefits in reducing fatigue and improving hematopoietic recovery in randomized controlled trials, though rigorous pharmacokinetic interaction studies with conventional agents remain ongoing. Moreover, China’s centralized electronic health record systems facilitate longitudinal monitoring of clonal dynamics (e.g., serial NGS-based minimal residual disease tracking), enabling earlier detection of progression.

Recovery and long-term management emphasize patient empowerment and structured surveillance. Patients should undergo comprehensive baseline assessment—including bone marrow biopsy with cytogenetics, next-generation sequencing (for ASXL1, SRSF2, U2AF1, EZH2, IDH1/2), and imaging (abdominal ultrasound or MRI for splenomegaly)—to inform prognosis and therapeutic decisions. Annual physical exams, CBC, LDH, and liver/kidney function tests are standard; bone marrow evaluation is repeated only upon clinical suspicion of progression (e.g., worsening cytopenias, increasing blasts >5%, new cytogenetic abnormalities). Psychosocial support is integral: MPNs carry high symptom burden and anxiety related to uncertainty of progression; cognitive behavioral therapy and peer-led support groups—increasingly available through platforms like the China MPN Alliance—are associated with improved coping and adherence. Patients must avoid nonsteroidal anti-inflammatory drugs (NSAIDs) due to bleeding risk, maintain hydration (especially during travel or illness), and promptly report signs of thrombosis (e.g., unilateral leg swelling, chest pain, sudden dyspnea) or transformation (e.g., persistent fever, night sweats, unexplained weight loss >10% in 6 months, progressive cytopenias). With contemporary risk-adapted strategies, median survival exceeds 15–20 years for PV and ET, and 5–7 years for intermediate-2/high-risk PMF—underscoring the importance of early diagnosis, precision risk stratification, and sustained multidisciplinary engagement.